LFB building first U.S. manufacturing facility

Pregnant belly

LFB USA, the Framingham, MA-based unit of France’s LFB Group, is building its first manufacturing facility in the U.S.

The biotech is investing $37 million to build a 65,000-square-foot manufacturing and laboratory facility in Marlborough, MA, according to the Milford Daily News. The company, which is getting incentives from the city, plans to add 50 jobs when the project is complete next year.

The plant will be used for early-stage processing of ATryn, a drug given to patients before surgery or childbirth who have a hereditary disease that can lead to blood clots. The drug will also be manufactured for rEVO Biologics, another unit of LFB, which is doing clinical trials on ATryn for treating the pregnancy complication preeclampsia.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

“This is our signature capital investment,” William Gavin, LFB USA president said during a groundbreaking event, the newspaper reported.  “We really need to scale this up for the market demand.”

- read the Daily News story 

Related Article: 
REVO looks to expand use of Atryn with preeclampsia PhIII

Suggested Articles

Higher operating costs were behind a 17% slide in pretax profits last year at Allergan’s Mayo, Ireland, facility that produces Botox.

After a global scare over Zantac contamination, generic metformin could be next in line as regulators test for possible carcinogen contamination.

PCI Pharma Services debuts expansion of its plant in Rockford, Illinois.